Evidence for a transcriptional signature of breast cancer - PubMed (original) (raw)
Comparative Study
doi: 10.1007/s10549-009-0505-z. Epub 2009 Sep 2.
Affiliations
- PMID: 19728083
- DOI: 10.1007/s10549-009-0505-z
Comparative Study
Evidence for a transcriptional signature of breast cancer
Yumei Feng et al. Breast Cancer Res Treat. 2010 Jul.
Abstract
Cancer arises from a step-wise accumulation of genetic and epigenetic changes in oncogenes and tumor suppressor genes, followed by changes in transcription and protein profiles. To identify the intrinsic transcriptional features of breast cancer and to explore in more detail the molecular basis of breast carcinogenesis, genes differentially expressed between cancers and their paired normal breast samples in nine breast cancer patients were screened using microarray. Nine normal breast tissues and 49 breast cancer tissue samples were then clustered based on the set of differentially expressed genes. A transcriptional signature of breast cancer consisting of 188 differentially expressed genes was identified. This signature allowed the normal breast tissues to be distinguished from all of the breast cancer samples, and primary breast cancers could be classified into two phenotype-associated subgroups with different ER status and clinical outcome. Furthermore, the classification accuracy of the set of differentially expressed genes was validated in publically available breast microarray data. Moreover, the differentially expressed genes could be grouped into five subclusters involved in different biological processes of carcinogenesis. Most genes in a given subcluster interacted within an independent subnetwork, and subnetworks could cross-talk through a set of signal molecules. Thus, the transcriptional signature identified here may be an intrinsic feature of breast cancer, and it may constitute to the molecular basis of breast carcinogenesis and different phenotypes of breast cancer.
Similar articles
- Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF, Xu XJ, Zhao Y, Liu ZB, Shen ZZ, Jin WR, Shao ZM. Li LF, et al. Breast Cancer Res Treat. 2009 Jan;113(2):231-7. doi: 10.1007/s10549-008-9925-4. Epub 2008 Feb 16. Breast Cancer Res Treat. 2009. PMID: 18278552 - A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA. Vendrell JA, et al. Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17. Breast Cancer Res. 2008. PMID: 18928543 Free PMC article. - Molecular targets in metastasis: lessons from genomic approaches.
Fingleton B. Fingleton B. Cancer Genomics Proteomics. 2007 May-Jun;4(3):211-21. Cancer Genomics Proteomics. 2007. PMID: 17878524 Review. - Regulation of estrogen receptor expression.
Martin MB, Saceda M, Garcia-Morales P, Gottardis MM. Martin MB, et al. Breast Cancer Res Treat. 1994;31(2-3):183-9. doi: 10.1007/BF00666152. Breast Cancer Res Treat. 1994. PMID: 7881098 Review. No abstract available.
Cited by
- Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma.
Qi Y, Xu F, Chen L, Li Y, Xu Z, Zhang Y, Wei W, Su N, Zhang T, Fan F, Wang X, Qin X, Zhang L, Liu Y, Xu P. Qi Y, et al. Oncotarget. 2016 Oct 18;7(42):68242-68252. doi: 10.18632/oncotarget.11921. Oncotarget. 2016. PMID: 27626164 Free PMC article. - The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway.
Pampalakis G, Obasuyi O, Papadodima O, Chatziioannou A, Zoumpourlis V, Sotiropoulou G. Pampalakis G, et al. Oncotarget. 2014 May 15;5(9):2390-403. doi: 10.18632/oncotarget.1235. Oncotarget. 2014. PMID: 24158494 Free PMC article. - Gene expression abnormalities in histologically normal breast epithelium from patients with luminal type of breast cancer.
Zubor P, Hatok J, Moricova P, Kajo K, Kapustova I, Mendelova A, Racay P, Danko J. Zubor P, et al. Mol Biol Rep. 2015 May;42(5):977-88. doi: 10.1007/s11033-014-3834-x. Epub 2014 Nov 19. Mol Biol Rep. 2015. PMID: 25407308 - Breast cancer cells obtain an osteomimetic feature via epithelial-mesenchymal transition that have undergone BMP2/RUNX2 signaling pathway induction.
Tan CC, Li GX, Tan LD, Du X, Li XQ, He R, Wang QS, Feng YM. Tan CC, et al. Oncotarget. 2016 Nov 29;7(48):79688-79705. doi: 10.18632/oncotarget.12939. Oncotarget. 2016. PMID: 27806311 Free PMC article. - FOXF2 reprograms breast cancer cells into bone metastasis seeds.
Wang S, Li GX, Tan CC, He R, Kang LJ, Lu JT, Li XQ, Wang QS, Liu PF, Zhai QL, Feng YM. Wang S, et al. Nat Commun. 2019 Jun 20;10(1):2707. doi: 10.1038/s41467-019-10379-7. Nat Commun. 2019. PMID: 31222004 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical